Oruka Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ORKA$109.50+4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30, 2024 | February 6, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $410,875 | $— |
| Subscription receivable | — | 1 |
| Prepaid expenses and other current assets | 2,074 | — |
| Total current assets | 412,949 | 1 |
| Property and equipment, net | 160 | — |
| Operating lease right-of-use asset | 938 | — |
| Other non-current assets | 43 | — |
| Total assets | $414,090 | $1 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,145 | $— |
| Accrued expenses and other current liabilities | 1,710 | — |
| Operating lease liability, current | 146 | — |
| Related party common stock warrant liability | 7,681 | — |
| Related party accounts payable and other current liabilities | 6,357 | — |
| Total current liabilities | 18,039 | — |
| Operating lease liability, non-current | 842 | — |
| Total liabilities | 18,881 | — |
| Commitment and contingencies (Note 11) | ||
| Series A convertible preferred stock, $0.0001 par value; no shares and 20,000,000 shares authorized as of September 30, 2024 and February 6, 2024, respectively; no shares issued and outstanding as of September 30, 2024 and February 6, 2024; liquidation preference of $0 as of September 30, 2024 and February 6, 2024 | — | — |
| Series A non-voting convertible preferred stock, $0.001 par value; 2,439 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 2,439 and no shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively | 52,841 | — |
| Stockholders’ equity: | ||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively | 2,931 | — |
| Common stock, $0.001 and $0.001 par value as of September 30, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 34,998,550 and 3,197,975 shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively | 35 | — |
| Additional paid-in capital | 397,345 | 1 |
| Accumulated deficit | (57,943) | — |
| Total stockholders’ equity | 342,368 | 1 |
| Total liabilities, convertible preferred stock and stockholders’ equity | $414,090 | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.